Cardiovascular Systems is a medical technology company. Co. has developed a patented orbital atherectomy systems (OAS) for both peripheral and coronary clinical applications. Co.'s peripheral artery disease products are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee, including calcified plaque, and address various limitations associated with other existing surgical, catheter and pharmacological treatment alternatives. Co.'s coronary artery disease (CAD) product, the Diamondback 360 Coronary OAS, is a catheter-based platform designed to facilitate stent delivery in patients with CAD. The CSII stock yearly return is shown above.
The yearly return on the CSII stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CSII annual return calculation with any dividends reinvested as applicable (on ex-dates).
|